Australian Clinical Labs Ltd - Asset Resilience Ratio

Latest as of December 2025: 4.11%

Australian Clinical Labs Ltd (ACL) has an Asset Resilience Ratio of 4.11% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

AU$23.14 Million

≈ $16.37 Million USD Cash + Short-term Investments

Total Assets

AU$562.50 Million

≈ $398.00 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how Australian Clinical Labs Ltd's Asset Resilience Ratio has changed over time. Check Australian Clinical Labs Ltd (ACL) strategic asset index to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Australian Clinical Labs Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Australian Clinical Labs Ltd (ACL) total market value.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	AU$22.43 Million	3.99%
Short-term Investments	AU$703.00K	0.12%
Total Liquid Assets	AU$23.14 Million	4.11%

Asset Resilience Insights

Limited Liquidity: Australian Clinical Labs Ltd maintains only 4.11% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Australian Clinical Labs Ltd Industry Peers by Asset Resilience Ratio

Compare Australian Clinical Labs Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
LONZA GROUP UNSP.ADR 1/10 F:LO3A	Diagnostics & Research	3.04%
Dr. Lal Path Labs Ltd. NSE:LALPATHLAB	Diagnostics & Research	13.43%
BGI Genomics Co Ltd SHE:300676	Diagnostics & Research	3.62%
Fleury S.A. SA:FLRY3	Diagnostics & Research	16.06%
Centro de Imagem Diagnósticos S.A SA:AALR3	Diagnostics & Research	4.77%
Inoviq Ltd AU:IIQ	Diagnostics & Research	56.29%
RHYTHM Biosciences Ltd AU:RHY	Diagnostics & Research	2.74%
Immunovia publ AB ST:IMMNOV	Diagnostics & Research	83.99%

Annual Asset Resilience Ratio for Australian Clinical Labs Ltd (2016–2025)

The table below shows the annual Asset Resilience Ratio data for Australian Clinical Labs Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-06-30	3.85%	AU$22.12 Million ≈ $15.65 Million	AU$574.84 Million ≈ $406.73 Million	0.00pp
2024-12-31	3.85%	AU$22.12 Million ≈ $15.65 Million	AU$574.84 Million ≈ $406.73 Million	-0.68pp
2024-06-30	4.53%	AU$26.84 Million ≈ $18.99 Million	AU$593.06 Million ≈ $419.63 Million	0.00pp
2023-12-31	4.53%	AU$26.84 Million ≈ $18.99 Million	AU$593.06 Million ≈ $419.63 Million	+0.97pp
2023-06-30	3.56%	AU$20.59 Million ≈ $14.57 Million	AU$578.91 Million ≈ $409.62 Million	0.00pp
2022-12-31	3.56%	AU$20.59 Million ≈ $14.57 Million	AU$578.91 Million ≈ $409.62 Million	+3.38pp
2022-06-30	0.18%	AU$1.13 Million ≈ $802.38K	AU$628.04 Million ≈ $444.38 Million	-4.20pp
2021-12-31	4.38%	AU$27.51 Million ≈ $19.46 Million	AU$628.04 Million ≈ $444.38 Million	+4.16pp
2021-06-30	0.22%	AU$1.05 Million ≈ $742.23K	AU$474.70 Million ≈ $335.88 Million	-7.42pp
2020-12-31	7.64%	AU$36.28 Million ≈ $25.67 Million	AU$474.70 Million ≈ $335.88 Million	+7.52pp
2020-06-30	0.12%	AU$435.00K ≈ $307.79K	AU$366.05 Million ≈ $259.01 Million	-9.52pp
2019-12-31	9.64%	AU$35.28 Million ≈ $24.97 Million	AU$366.05 Million ≈ $259.01 Million	+8.99pp
2019-06-30	0.65%	AU$1.00 Million ≈ $708.27K	AU$153.61 Million ≈ $108.69 Million	-2.69pp
2018-12-31	3.34%	AU$5.13 Million ≈ $3.63 Million	AU$153.61 Million ≈ $108.69 Million	+0.89pp
2018-06-30	2.45%	AU$2.91 Million ≈ $2.06 Million	AU$119.06 Million ≈ $84.24 Million	-5.77pp
2017-12-31	8.22%	AU$9.78 Million ≈ $6.92 Million	AU$119.06 Million ≈ $84.24 Million	+7.97pp
2017-06-30	0.25%	AU$301.00K ≈ $212.98K	AU$120.89 Million ≈ $85.54 Million	-5.82pp
2016-12-31	6.07%	AU$7.34 Million ≈ $5.19 Million	AU$120.89 Million ≈ $85.54 Million	--

pp = percentage points

About Australian Clinical Labs Ltd

AU:ACL Australia Diagnostics & Research

Market Cap

$309.40 Million

AU$437.28 Million AUD

Market Cap Rank

#14467 Global

#390 in Australia

Share Price

AU$2.33

Change (1 day)

-1.27%

52-Week Range

AU$1.84 - AU$2.92

All Time High

AU$5.09